Menopause Practice Questions

Q: Menopause is defined as?

Cessation of menses for one year. ***Cessation of menses for one year*** - Menopause is clinically defined as **12 consecutive months of amenorrhea** (absence of menstruation) in women of appropriate age. - This definition is crucial for distinguishing menopause from **perimenopause**, where menstrual cycles can be irregular. *Presence of hot flashes* - **Hot flashes** are a common symptom of menopause and perimenopause, but their presence *alone* does not define menopause. - Many women experience hot flashes for years **before** or after the official menopausal transition. *Cessation of menses for six months* - A 6-month period of amenorrhea is **insufficient** to diagnose menopause, as menstrual cycles can become irregular during perimenopause and then resume. - This duration might be indicative of **oligomenorrhea** or other gynecological issues, not necessarily permanent ovarian failure. *Cessation of menses for two years* - While a 2-year cessation of menses would certainly indicate menopause, the generally accepted and more precise clinical definition is **one year (12 months)**. - Using a 2-year cessation would **delay diagnosis** unnecessarily for a significant period.

Q: Which of the following is not a common symptom of menopause?

Intermittent hypotension. ***Intermittent hypotension*** - **Intermittent hypotension** is not primarily associated with menopause; rather, **hypertension** and increased cardiovascular risk can be observed after menopause due to hormonal changes - While many bodily changes occur during menopause, fluctuating decreases in blood pressure are not typical hallmark symptoms - Estrogen loss may actually contribute to increased blood pressure through effects on vascular function and lipid metabolism *Night sweats* - **Night sweats** are a common **vasomotor symptom** during menopause, often accompanying hot flashes - Caused by hormonal fluctuations, particularly drops in **estrogen levels**, affecting the body's **thermoregulation** - Can significantly disrupt sleep and affect quality of life *Decreased libido* - A **decrease in libido** is a frequently reported symptom during menopause, attributed to lower **estrogen** and **testosterone** levels - Hormonal changes can lead to **vaginal dryness** and discomfort during intercourse, further contributing to reduced sexual desire - Psychological factors and sleep disturbances may also contribute *Hot flushes* - **Hot flushes** (hot flashes) are the most characteristic **vasomotor symptom** of menopause, experienced by 60-80% of women - Involve sudden sensations of heat, sweating, and flushed skin, often triggered by hormonal shifts, specifically fluctuating **estrogen** - Typically last 30 seconds to several minutes and may occur multiple times daily

Q: What is the primary use of Tibolone in post-menopausal women?

Hormone replacement therapy. ***Correct: Hormone replacement therapy*** - **Tibolone** is a synthetic steroid with estrogenic, progestogenic, and weak androgenic properties, primarily used to alleviate **menopausal symptoms** such as hot flashes, vaginal dryness, and mood disturbances. - It serves as an alternative to conventional **hormone replacement therapy (HRT)**, offering symptomatic relief and preventing **osteoporosis** in post-menopausal women. *Incorrect: Treatment of fibroids* - **Fibroids** are benign uterine growths that typically respond to treatments that reduce estrogen levels or directly target the fibroid tissue. Tibolone, with its estrogenic activity, is generally **not used** for fibroid treatment and could potentially exacerbate their growth. - Common treatments for fibroids include GnRH agonists, uterine artery embolization, or surgical removal, none of which is tibolone. *Incorrect: Management of endometriosis* - **Endometriosis** is a condition where endometrial-like tissue grows outside the uterus, and its management often involves suppressing ovarian function to reduce estrogen levels, which fuels its growth. Tibolone's estrogenic effects mean it is generally **contraindicated** in active endometriosis. - Treatments often include GnRH agonists, progesterone-only therapies, or surgery to remove endometrial implants. *Incorrect: Treatment of anovulatory infertility* - **Anovulatory infertility** is characterized by irregular or absent ovulation, often treated with medications to induce ovulation. Tibolone is a steroid that can **suppress ovulation** and is therefore not used to promote conception. - Fertility treatments typically involve clomiphene citrate, letrozole, or gonadotropins to stimulate ovulation.

Q: What is the primary cancer risk associated with the simultaneous administration of estrogen and progesterone in hormone replacement therapy?

Breast cancer. ***Breast cancer*** - **Combined estrogen and progesterone** in hormone replacement therapy (HRT) has been linked to an increased risk of **breast cancer**, particularly with long-term use. - The addition of progesterone to estrogen helps mitigate the risk of **endometrial cancer** but does not eliminate the breast cancer risk, and may in fact contribute to it. *Cervical cancer* - **Cervical cancer** is primarily caused by persistent infection with **high-risk human papillomavirus (HPV)**. - There is no direct evidence to suggest that combined estrogen and progesterone HRT significantly increases the risk of cervical cancer. *Both a and b* - While HRT with combined estrogen and progesterone increases the risk of **breast cancer**, it does not significantly increase the risk of **cervical cancer**. - Attributing an increased risk for both conditions due to combined HRT is inaccurate based on current evidence. *Ovarian cancer* - Some studies suggest a possible **slight increase in ovarian cancer risk** with combined HRT, but this finding is **inconsistent** across research and the risk is generally considered to be small if present. - The most significant and well-established cancer risk with combined HRT is **breast cancer**.

Q: What is one of the benefits of hormone replacement therapy (HRT) in postmenopausal women?

Bone density. ***Bone density*** - HRT with estrogen has been shown to **prevent bone loss** and reduce the risk of **osteoporotic fractures** in postmenopausal women. - Estrogen plays a crucial role in maintaining **bone mineral density** by inhibiting osteoclast activity. *Dementia* - While earlier observational studies suggested a benefit, large randomized controlled trials like the **Women's Health Initiative (WHI)** found no protective effect of HRT on **dementia** and even showed an increased risk in older women initiating HRT. - The use of HRT is **not recommended for the prevention or treatment of dementia.** *Coronary artery disease* - The WHI study demonstrated that combined estrogen-progestin HRT actually **increased the risk of coronary artery disease** events, especially in older women initiating HRT years after menopause. - HRT is **not indicated for the primary or secondary prevention of cardiovascular disease**. *Endometrial cancer* - Unopposed estrogen therapy in women with an intact uterus **increases the risk of endometrial hyperplasia and cancer**. - To counteract this risk, **progestin is added** to estrogen therapy for women with a uterus to protect the endometrium.

Q: Which of the following treatments is used for vulvar atrophy and itching?

Estrogen ointment. ***Estrogen ointment*** * **Estrogen ointment** is the primary treatment for vulvar atrophy and itching because it directly addresses the underlying cause of these symptoms, which is the decline in estrogen levels after **menopause**. * By restoring estrogen to the vulvar tissues, it helps to **thicken the epithelium**, improve blood flow, and increase lubrication, thereby alleviating dryness, itching, and discomfort. *Antihistamines* * **Antihistamines** are used to treat allergic reactions and reduce itching associated with conditions like hives or insect bites, but they do not address the hormonal deficiency causing vulvar atrophy. * While they might temporarily relieve some itching, they do not treat the underlying **tissue thinning** and dryness characteristic of vulvar atrophy. *Tamoxifen* * **Tamoxifen** is a selective estrogen receptor modulator (SERM) primarily used in the treatment and prevention of breast cancer, as it blocks estrogen's effects in breast tissue. * However, in vulvovaginal tissues, **tamoxifen can actually worsen atrophy and dryness** due to its anti-estrogenic effects, making it an inappropriate treatment for vulvar atrophy. *None of the options* * This option is incorrect because **estrogen ointment** is a well-established and effective treatment specifically designed to address vulvar atrophy and associated itching, by restoring estrogen levels to the affected tissues.

Q: What does HT stand for in the context of menopausal treatment?

Hormone Therapy. ***Hormone Therapy*** - **HT** is the widely accepted abbreviation for **Hormone Therapy** in the context of menopausal treatment. - This treatment involves administering **estrogen** and/or **progestin** to alleviate menopausal symptoms such as hot flashes, vaginal dryness, and bone loss. - HT is the standard terminology used in current medical practice and literature. *Hysterectomy Treatment* - While hysterectomy is a gynecological procedure, "Hysterectomy Treatment" is not abbreviated as HT in medical terminology. - Hysterectomy refers to surgical removal of the uterus, not a treatment abbreviation. *Hormonal Transplant* - This is not a recognized medical term or treatment modality. - "Hormonal Transplant" is not used in clinical practice and does not abbreviate to HT. *Hyperthermia Therapy* - While this could theoretically abbreviate to HT, it refers to a cancer treatment using heat, not a menopausal treatment. - In the specific context of menopausal treatment, HT exclusively refers to Hormone Therapy.

Q: What is the primary hormonal cause of hot flushes experienced during menopause?

Decreased estrogen levels. ***Decreased estrogen levels*** - **Decreased estrogen** is the primary hormonal change during menopause, leading to thermoregulatory dysfunction in the hypothalamus. - This hormonal imbalance causes the **vasomotor symptoms** like hot flushes and night sweats. *Increased noradrenaline* - While **noradrenaline** (norepinephrine) is involved in thermoregulation, its increase is a **secondary event** triggered by the initial estrogen deficiency, not the primary cause. - Increased noradrenaline can exacerbate the **vasodilation** and heat dissipation experienced during a hot flush. *Increased noradrenaline with normal estrogen levels* - This option is incorrect because hot flushes are characteristic of menopause, which is defined by **decreased estrogen levels**. - **Normal estrogen levels** would typically prevent the severe thermoregulatory instability that causes hot flushes. *Both increased noradrenaline and decreased estrogen levels* - Although both factors are involved, the question asks for the **primary hormonal cause**. **Decreased estrogen** initiates the cascade of events, including the subsequent alteration of neurotransmitter levels like noradrenaline. - Noradrenaline's role is more of a **mediator** in the physiological response to the primary estrogen deficiency.

Q: Which among the following is an absolute contraindication of Hormone replacement therapy?

Breast carcinoma. ### Breast carcinoma - Hormone replacement therapy (HRT) is **contraindicated** in breast carcinoma because many breast cancers are **estrogen-receptor positive**, meaning estrogen can stimulate their growth [1]. - Using HRT in patients with a history of breast cancer significantly increases the risk of **recurrence** or **progression** of the disease [1]. *Endometriosis* - Endometriosis is not an **absolute contraindication**; HRT can sometimes be used in women with a history of endometriosis, especially if a hysterectomy and bilateral oophorectomy have been performed. - However, unopposed estrogen therapy might **exacerbate** remaining endometrial implants, so a combined estrogen-progestin regimen is typically preferred [1]. *Heart disease* - While HRT has been shown to have **risks** in women with established coronary heart disease, it is not an absolute contraindication for all forms of heart disease. - The **Women's Health Initiative study** demonstrated increased cardiovascular events in older women initiating HRT, but current guidelines suggest that timing of initiation is crucial and benefits may outweigh risks for younger postmenopausal women. *Osteoarthritis* - Osteoarthritis is **not a contraindication** to HRT; in fact, some studies suggest that estrogen may have protective effects on cartilage [2]. - HRT is neither a treatment nor a contraindication for osteoarthritis and does not significantly impact its progression or severity [2].

Q: What is the investigation of choice in postmenopausal bleeding?

Ultrasound. ***Ultrasound*** - An initial **transvaginal ultrasound** is the investigation of choice to assess the endometrial thickness in postmenopausal bleeding. An endometrial thickness of >4-5mm often warrants further investigation. - It helps in **ruling out endometrial pathologies** like hyperplasia, polyps, or carcinoma. *PAP smear* - A **PAP smear** is a screening test for cervical cancer, not typically used to investigate postmenopausal bleeding originating from the uterus. - While it can detect some endometrial cells, it is **not sensitive** or specific enough to diagnose the cause of postmenopausal bleeding. *Laparoscopy* - **Laparoscopy** is a surgical procedure used to visualize pelvic organs and is generally employed for diagnosing and treating conditions like endometriosis, ovarian cysts, or ectopic pregnancies. - It is **not the initial investigation** for postmenopausal bleeding and is too invasive for primary diagnosis unless other methods have failed or a specific pathology is suspected. *Fractional curettage* - **Fractional curettage** involves scraping the lining of the cervix and uterus to obtain tissue samples for histological examination. - While it can be diagnostic for endometrial pathology, it is typically performed **after an initial ultrasound** has identified increased endometrial thickness or other suspicious findings, and less commonly as a standalone initial investigation.

Question 1

Menopause is defined as?

Accepted Answer

Cessation of menses for one year

Answer

Presence of hot flashes

Answer

Cessation of menses for six months

Answer

Cessation of menses for two years

Question 2

Which of the following is not a common symptom of menopause?

Accepted Answer

Intermittent hypotension

Answer

Night sweats

Answer

Decreased libido

Answer

Hot flushes

Question 3

What is the primary use of Tibolone in post-menopausal women?

Accepted Answer

Hormone replacement therapy

Answer

Treatment of fibroids

Answer

Management of endometriosis

Answer

Treatment of anovulatory infertility

Question 4

What is the primary cancer risk associated with the simultaneous administration of estrogen and progesterone in hormone replacement therapy?

Accepted Answer

Breast cancer

Answer

Cervical cancer

Answer

Both a and b

Answer

Ovarian cancer

Question 5

What is one of the benefits of hormone replacement therapy (HRT) in postmenopausal women?

Accepted Answer

Bone density

Answer

Coronary artery disease

Answer

Endometrial cancer

Answer

Dementia

Question 6

Which of the following treatments is used for vulvar atrophy and itching?

Accepted Answer

Estrogen ointment

Answer

Antihistamines

Answer

Tamoxifen

Answer

None of the options

Question 7

What does HT stand for in the context of menopausal treatment?

Accepted Answer

Hormone Therapy

Answer

Hysterectomy Treatment

Answer

Hormonal Transplant

Answer

Hyperthermia Therapy

Question 8

What is the primary hormonal cause of hot flushes experienced during menopause?

Accepted Answer

Decreased estrogen levels

Answer

Increased noradrenaline with normal estrogen levels

Answer

Increased noradrenaline

Answer

Both increased noradrenaline and decreased estrogen levels

Question 9

Which among the following is an absolute contraindication of Hormone replacement therapy?

Accepted Answer

Breast carcinoma

Answer

Endometriosis

Answer

Heart disease

Answer

Osteoarthritis

Question 10

What is the investigation of choice in postmenopausal bleeding?

Accepted Answer

Ultrasound

Answer

PAP smear

Answer

Laparoscopy

Answer

Fractional curettage

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?